ClinicalTrials.gg
RecruitingNCT07508020Updated Apr 27, 2026

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

A Phase 1 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
17th of 24
120 · median 360
Started
2026
with 18 others
Phase 1
9 of 24
6 open now
Primary completion
2028-01
later than 1 of 19 live
Registered
9th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 17th largest by planned enrollment, is one of 19 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 1 of the 19 other live ones, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

The purpose of this clinical study is to look at if/how much NNC0487-0111 affects food intake, appetite and metabolism in participants with obesity when compared to placebo. There are 2 study treatments in this study. Participants will inject the study treatment under the skin of your stomach once a week. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants will get is decided by chance.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female (sex at birth).
  • Age 18-64 years (both inclusive) at the time of signing the .
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.
  • Overweight should be due to excess adipose tissue, as judged by the investigator.

Key Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • History of type 1 or type 2 diabetes mellitus.
  • (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole [mmol/mol]) at screening.
  • Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and/or amylin-based therapy due to tolerability issues.
  • Any body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening.
  • Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111

    Participants will be randomized to receive 1 of the different dose levels of NNC0487-0111 subcutaneously once weekly.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly.

    Drug: Placebo (matched to NNC0487-0111)

Interventions

  • NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.

  • DrugPlacebo (matched to NNC0487-0111)

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.

06

What researchers measure

Primary outcomes

  1. Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126

    Measured as percentage change of energy.

    Time frame: From Baseline to Day 126

  2. Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182

    Measured as percentage change of energy.

    Time frame: From Baseline to Day 182

  3. Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238

    Measured as percentage change of energy.

    Time frame: From Baseline to Day 238

Secondary outcomes

  1. Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126

    Measured as kilojoules (kJ).

    Time frame: From Baseline to Day 126

  2. Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182

    Measured as kJ.

    Time frame: From Baseline to Day 182

  3. Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238

    Measured as kJ.

    Time frame: From Baseline to Day 238

  4. Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 126

    Measured as grams.

    Time frame: From Baseline to Day 126

  5. Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 182

    Measured as grams.

    Time frame: From Baseline to Day 182

  6. Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 238

    Measured as grams.

    Time frame: From Baseline to Day 238

  7. Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 378

    Measured as percentage change of energy.

    Time frame: From Baseline to Day 378

  8. Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 378

    Measured as kJ.

    Time frame: From Baseline to Day 378

  9. Change from baseline in total amount of food consumed during ad libitum breakfast, lunch, evening meal and snack box to Day 378

    Measured as grams.

    Time frame: From Baseline to Day 378

  10. Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 126

    Measured as kJ.

    Time frame: From Baseline to Day 126

  11. Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 182

    Measured as kJ.

    Time frame: From Baseline to Day 182

  12. Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 238

    Measured as kJ.

    Time frame: From Baseline to Day 238

  13. Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 378

    Measured as kJ.

    Time frame: From Baseline to Day 378

  14. Relative change from Day 19 in body weight to Day 131

    Measured as percentage change of body weight.

    Time frame: From Day 19 to Day 131

  15. Relative change from Day 19 in body weight to Day 187

    Measured as percentage change of body weight.

    Time frame: From Day 19 to Day 187

  16. Relative change from Day 19 in body weight to Day 243

    Measured as percentage change of body weight.

    Time frame: From Day 19 to Day 243

  17. Relative change from Day 19 in body weight to Day 383

    Measured as percentage change of body weight.

    Time frame: From Day 19 to Day 383

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 21 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 2, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Jan 19, 2028
CompletionEst.
Jan 22, 2028
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07508020
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Mar 30, 2026
Primary completion
Jan 19, 2028 (estimated)
Completion
Jan 22, 2028 (estimated)
Last update
Apr 27, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion